Agomab Therapeutics Nv (AGMB)

Currency in USD
10.74
+0.27(+2.58%)
Closed·
10.69+0.03(+0.28%)
·
AGMB is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
10.1710.99
52 wk Range
9.0017.45
Key Statistics
Prev. Close
10.47
Open
10.35
Day's Range
10.17-10.99
52 wk Range
9-17.45
Volume
198.05K
Average Vol. (3m)
223.9K
1-Year Change
-
Book Value / Share
-
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
AGMB Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
32.00
Upside
+197.95%
Members' Sentiments
Bearish
Bullish
ProTips
Analysts do not anticipate the company will be profitable this year

Agomab Therapeutics Nv News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Buy

AgomAb Therapeutics NV, a clinical-stage biopharmaceutical company, develops novel disease-modifying therapies for immunology and inflammatory diseases with a focus on chronic fibrotic indications with unmet medical needs. The company’s product pipeline includes Ontunisertib (AGMB-129), an oral gastrointestinal-restricted small molecule inhibitor of ALK5 or TGFßR1 for the treatment of Fibrostenosing Crohn’s disease, which is in Phase 2a clinical trials; and AGMB-447, an inhaled small molecule inhibitor of ALK5 or TGFßR1 for the treatment of idiopathic pulmonary fibrosis that is in Phase 1 clinical trials. It also develops AGMB-101, a HGF-mimetic monoclonal antibody that acts through agonism or stimulation of the MET receptor and has demonstrated antifibrotic and regenerative activity in preclinical models. The company was incorporated in 2017 and is headquartered in Antwerp, Belgium.

Compare AGMB to Peers and Sector

Metrics to compare
AGMB
Peers
Sector
Relationship
P/E Ratio
−6.1x−9.8x−0.5x
PEG Ratio
-0.260.00
Price / Book
-−1.8x2.6x
Price / LTM Sales
-45.5x3.2x
Upside (Analyst Target)
198.0%647.2%45.7%
Fair Value Upside
Unlock6.6%4.8%Unlock

Analyst Ratings

3 Buy
0 Hold
0 Sell
Ratings:
3 analysts
Overall Consensus
Buy

Analysts 12-Month Price Target:

Average 32.00
(+197.95% Upside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate

Earnings

Latest Release
Feb 25, 2026
EPS / Forecast
-0.44 / --
Revenue / Forecast
-- / --
EPS Revisions
Last 90 days

AGMB Income Statement

People Also Watch

24.73
SGP
+0.86%
58.93
FOUR_pa
+0.31%
5.44
YDES
-4.65%
10.84
EXOZ
-1.45%

FAQ

What Is the Agomab Therapeutics (AGMB) Stock Price Today?

The Agomab Therapeutics stock price today is 10.74 USD.

What Stock Exchange Does Agomab Therapeutics Trade On?

Agomab Therapeutics is listed and trades on the Nasdaq Stock Exchange.

What Is the Stock Symbol for Agomab Therapeutics?

The stock symbol for Agomab Therapeutics is "AGMB."

What Is the Agomab Therapeutics Market Cap?

As of today, Agomab Therapeutics market cap is 510.27M USD.

What Is Agomab Therapeutics's Earnings Per Share (TTM)?

The Agomab Therapeutics EPS (TTM) is -2,890.60.

When Is the Next Agomab Therapeutics Earnings Date?

Agomab Therapeutics will release its next earnings report on Jun 03, 2026.

From a Technical Analysis Perspective, Is AGMB a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Sell.

How Many Times Has Agomab Therapeutics Stock Split?

Agomab Therapeutics has split 0 times.

How Many Employees Does Agomab Therapeutics Have?

Agomab Therapeutics has 62 employees.

What is the current trading status of Agomab Therapeutics (AGMB)?

As of Apr 16, 2026, Agomab Therapeutics (AGMB) is trading at a price of 10.74 USD, with a previous close of 10.47 USD. The stock has fluctuated within a day range of 10.17 USD to 10.99 USD, while its 52-week range spans from 9.00 USD to 17.45 USD.

What Is Agomab Therapeutics (AGMB) Price Target According to Analysts?

The average 12-month price target for Agomab Therapeutics is 32.00 USD, with a high estimate of 36 USD and a low estimate of 28 USD. 3 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Buy. The stock has an +197.95% Upside potential.

What Is the AGMB After Hours Price?

AGMB's last after hours stock price is 10.69 USD, the stock has decreased by 0.03, or 0.28%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.